Literature DB >> 9390098

Drug treatment of migraine: Part I. Acute therapy and drug-rebound headache.

K L Moore1, S L Noble.   

Abstract

Most migraine patients need only abortive treatment for their headaches. By the time they present to a physician, they have already tried many over-the-counter medications for headache relief. Prioritizing treatment according to headache severity and associated symptoms will help the physician determine the most appropriate medications to use. Narcotics should be reserved for use only in patients unresponsive to adequate trials of non-narcotic agents. In some patients, the recurrent nausea and vomiting can be as disabling as the pain; antiemetic agents are an important adjunct to analgesic therapy in these patients. Sumatriptan and dihydroergotamine are more expensive than other migraine agents but have distinct therapeutic advantages in patients with moderate to severe headaches. Some patients experience rebound headache from overuse of analgesics and other headache medications. Educating patients about self-help measures and avoidance of triggers is an important element in the effective management of migraine headaches.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390098

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  2 in total

Review 1.  Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence.

Authors:  Ian Colman; Benjamin W Friedman; Michael D Brown; Grant D Innes; Eric Grafstein; Ted E Roberts; Brian H Rowe
Journal:  BMJ       Date:  2008-06-09

2.  Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial.

Authors:  Hassan Soleimanpour; Rouzbeh Rajaei Ghafouri; Aliakbar Taheraghdam; Dawood Aghamohammadi; Sohrab Negargar; Samad E J Golzari; Mohsen Abbasnezhad
Journal:  BMC Neurol       Date:  2012-09-29       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.